HER3/ErbB3, an emerging cancer therapeutic target.
Houston, United States. In Acta Biochim Biophys Sin (shanghai), Jan 2016
HER3 is a member of the HER (EGFR/ErbB) receptor family consisting of four closely related type 1 transmembrane receptors (EGFR, HER2, HER3, and HER4).
Genomic classification of lung cancer: toward a personalized treatment.
In Tunis Med, Jun 2015
Upon binding to its ligands, EGFRforms homodimers or heterodimers with other family members(ERBB2, ERBB3 or ERBB4),which inactivate intrinsic receptor tyrosine kinase activity and trigger a phosphorylation cascade of specific tyrosine residues within their cytoplasmicregulatory domains(3).
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
Budapest, Hungary. In Curr Cancer Drug Targets, 2014
These include HER2 amplification, impaired access to the binding site (p95HER2, Δ16HER-2, MUC4), augmented signaling through other ERBB family receptors (HER1, HER3, HER4) and their ligands, activation of HER2 targets by alternate heterodimers (EphA2, IGF-1R, GDF15, MUC1*), signaling triggered by downstream members (PIK3CA, PTEN, SRC, mTOR), altered expression of cell cycle and apoptotic regulators (CDKs, p27(kip1), Bcl-2), hormone receptor status, resistance to antibody-dependent cellular cytotoxicity (FcγR), and altered miRNA expression signatures.
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
More papers using
Barcelona, Spain. In J Clin Oncol, 2014
PATIENTS AND METHODS: Mandatory tumor and serum samples were collected (N = 808; 58% to 99.8% were assessable), and amphiregulin, betacellulin, epidermal growth factor (EGF), transforming growth factor alpha, EGF receptor, HER2, HER3, insulin-like growth factor 1 receptor, PTEN, phosphorylated AKT, PIK3CA, CMYC, serum HER2 extracellular domain (sHER2), and FCγR were assessed using appropriate assays.